FDA staff says Biogen's ALS drug may have a 'clinical benefit' on a rare form of the disease

The FDA staff on Monday said Biogen's investigational ALS drug tofersen may have a "clinical benefit" on a rare and aggressive form of the disease.

from Health and Science https://ift.tt/p0OXnfQ
https://ift.tt/7Tbsc3i
https://ift.tt/wxKli5o